Ezetimibe Is an Inhibitor of Tumor Angiogenesis

Epidemiological and preclinical observations have suggested a role for one or more products of the mevalonate/cholesterol biosynthesis pathway in the progression of prostate cancer. In this study, we used ezetimibe (Zetia), a specific, FDA-approved, cholesterol uptake-blocking drug, in combination w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Solomon, Keith R., Pelton, Kristine, Boucher, Kelly, Joo, Jinsoo, Tully, Christopher, Zurakowski, David, Schaffner, Carl P., Kim, Jayoung, Freeman, Michael R.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Investigative Pathology 2009
Assuntos:
Regular Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2665761/
https://ncbi.nlm.nih.gov/pubmed/19179610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2353/ajpath.2009.080551
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares